查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2018470

神經血管導管市場：依產品類型、材料、尺寸、應用和最終用戶分類－2026-2032年全球市場預測

Neurovascular Catheters Market by Product Type, Material, Size, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，神經血管導管市場價值將達到 54 億美元，到 2026 年將成長至 59.7 億美元，到 2032 年將達到 124.5 億美元，年複合成長率為 12.64%。

主要市場統計數據
基準年 2025 54億美元
預計年份：2026年 59.7億美元
預測年份 2032 124.5億美元
複合年成長率 (%) 12.64%

本文概述了神經血管導管在現代血管內治療中的關鍵作用，以及影響該領域的臨床、技術和採購壓力。

神經血管導管在介入性神經病學、血管內治療和急性中風治療的交叉領域中發揮著至關重要的作用。這些裝置能夠幫助醫生進入腦血管，並在血管內進行導航，輸送治療藥物和植入，從而實現從診斷性血管造影術到複雜動脈瘤修復和血栓切除等多種手術。微導管工程技術的進步、導管尖端設計的改進以及新材料的應用，共同提升了導管的輸送性能和臨床精準度，縮短了手術時間，並擴大了可治療病變的範圍。隨著臨床醫生尋求微創方法和更廣泛的適應症，導管的性能特徵，例如順應性、扭矩響應性和管腔完整性，變得至關重要。

了解正在重塑神經血管導管的設計、部署趨勢和價值提案的關鍵技術、臨床和監管變化。

神經血管器械市場正經歷多項變革，其驅動力包括技術進步、手術流程標準化以及不斷變化的醫療保險報銷要求。工程師致力於研發兼具柔軟性和剛性的混合結構，使其能夠在長而曲折的路徑上順暢穿行，同時確保器械輸送過程中的支撐力。同時，諸如血流導向裝置和專用栓塞器等輔助裝置的普及，正在改變導管的功能需求，從而催生了對差異化微導管的需求，這些微導管需針對新型治療方法進行最佳化。

本研究評估了 2025 年美國關稅調整的引入將如何改變整個供應鏈的籌資策略、生產地點和競爭格局。

2025年美國關稅政策的變化將成為依賴複雜多層供應鏈的製造商、經銷商和醫院採購機構的轉捩點。某些醫療組件進口關稅的提高可能會推高醫療器材的生產成本，醫療設備通常包含來自全球供應商的特殊聚合物、造影劑或精密加工的金屬合金。為此，各機構可能會重新評估籌資策略、生產地點和庫存緩衝，以減輕關稅對利潤率帶來的壓力。

基於詳細細分的洞察揭示了產品類型、材料、尺寸、應用和最終用戶環境如何相互作用，從而影響設計優先順序和部署路徑。

透過對產品、材料、尺寸、應用和最終用戶進行詳細的細分分析，揭示了臨床需求與技術方法的交匯點。在考慮產品特性時，診斷導管的特徵在於其在血管造影術和壓力測量中的作用。引導管的特點在於其加強結構和軟頭設計，這些設計兼顧了支撐作用和與血管的非侵入性接觸。微導管提供導絲引導和快速更換選項，這會影響手術流程和與相關設備的兼容性。材料的選擇對器械的性能起著至關重要的作用；聚醚嵌段醯胺因其柔軟性和耐久性而備受青睞，聚醯亞胺用於需要尺寸穩定性和耐熱性的場合，而聚四氟乙烯則因其潤滑性和低摩擦性而被選中。 1.2F–1.5F、1.6F–2.0F 和 2.1F–2.5F 的尺寸範圍與解剖路徑的深度以及可透過特定管腔輸送的器械的複雜程度直接相關。

對美洲、歐洲、中東和非洲以及亞太地區的區域趨勢和戰略挑戰進行比較，這將決定商業化和監管的方法。

區域趨勢對監管預期、臨床實務模式和供應鏈物流有顯著影響。在美洲，對病患就醫模式和基於療效的合約的關注，推動了對能夠展現手術效率和可靠性的醫療設備的需求，而分銷網路則優先考慮能夠提供快速服務、培訓和售後支援的供應商。某些市場複雜的報銷機制和醫院整合進一步影響了採購計劃，並削弱了大規模綜合醫療服務網路的議價能力。

本分析考察了成熟的全球醫療設備製造商、敏捷的創新者和策略製造夥伴的競爭優勢，這些優勢決定了商業性主導地位。

神經血管導管領域的競爭格局由成熟的醫療設備製造商和專注於特定技術優勢的專業創新者組成。該領域的領導企業通常擁有涵蓋診斷、引導和微導管等產品的多層次產品組合，並將產品創新與對臨床醫生培訓和真實臨床數據收集的投資相結合。這些企業優先考慮健全的品管系統、清晰的監管合規流程以及支援全球分銷和服務網路的能力。

為領導者提供兩方面的可操作建議，以加強供應鏈韌性，加速具有臨床意義的創新，並使商業模式與醫療保健優先事項保持一致。

產業領導企業應採取雙管齊下的策略，既要保障短期業務永續營運，也要持續投資於臨床和技術差異化。短期內，他們需要審查關鍵材料的採購和分類，以降低關稅波動帶來的風險，同時加快供應商認證計劃，分散地域風險。同時，增加對庫存管理和需求預測的投資，將有助於減少供應鏈中斷對營運的影響，並確保對時間要求嚴格的神經血管外科手術的穩定供應。

我們透過透明、基於證據的調查方法來支持策略決策，該方法結合了對臨床醫生的訪談、技術評估、監管分析和供應鏈壓力測試。

本研究途徑採用多層次證據框架，整合了臨床醫師的原始資訊、技術評估、監管分析和供應鏈審計。關鍵見解是透過對介入性神經神經科、神經介入放射科醫生和採購經理的結構化訪談收集的，並輔以與設計工程師和材料科學家的技術諮詢。二級資訊來源包括同行評審的臨床文獻、醫療醫療設備標籤標準和公開的監管文件，這些資料揭示了醫療設備性能的背景和安全考慮。供應鏈評估包括對原料投入、製造流程和物流樞紐進行梳理，以識別潛在的薄弱環節和提升韌性的機會。

我們整合了臨床、技術和營運要求，並從策略上明確了相關人員應關注的領域，以維持部署並降低風險。

神經血管導管介入領域的特點是技術快速發展、臨床方案不斷演變，以及供應鏈和監管環境日益複雜。醫療設備製造商和醫療機構都面臨兩大挑戰：既要為精細的腦血管介入手術提供高性能解決方案，又要維持穩健且經濟高效的供應鏈。雖然材料創新和精密的導管設計拓展了手術的可能性，但其應用取決於經證實有效的臨床和操作效益，而這些效益必須能夠引起醫療採購負責人和臨床團隊的共鳴。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 神經血管導管市場：依產品類型分類

  • 診斷導管
    • 血管造影術
    • 壓力測量
  • 引導管
    • 加強型
    • 軟頭
  • 微導管
    • 越過電線
    • 快速交換

第9章：神經血管導管市場：依材料分類

  • 聚醚嵌段醯胺
  • 聚醯亞胺
  • 聚四氟乙烯

第10章 神經血管導管市場：依尺寸分類

  • 1.2F～1.5F
  • 1.6F～2.0F
  • 2.1F～2.5F

第11章 神經血管導管市場：依應用領域分類

  • 動脈瘤治療
    • 血管內彈簧圈療法
    • 血液灌流裝置
  • 栓塞
    • 液體栓塞
    • 顆粒栓塞
  • 血栓切除術

第12章 神經血管導管市場：依最終用戶分類

  • 門診手術中心
  • 醫院
    • 社區醫療保健
    • 三級醫療保健
  • 專科診所

第13章：神經血管導管市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 神經血管導管市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 神經血管導管市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國神經血管導管市場

第17章：中國神經血管導管市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • Acandis GmbH
  • Asahi Intecc Co., Ltd.
  • B. Braun Melsungen AG
  • Balt Extrusion
  • Becton, Dickinson and Company
  • Boston Scientific Corporation
  • Cook Medical LLC
  • ICU Medical, Inc.
  • Imperative Care Inc.
  • Inari Medical, Inc.
  • Integer Holdings Corporation
  • Integra LifeSciences Holdings Corporation
  • Johnson & Johnson Services, Inc.
  • Medtronic plc
  • Merit Medical Systems, Inc.
  • MicroPort Scientific Corporation
  • Penumbra, Inc.
  • Phenox GmbH
  • Rapid Medical Ltd.
  • Stryker Corporation
  • Teleflex Incorporated
  • Terumo Company
  • Terumo Corporation
  • Zeus Industrial Products, Inc.
Product Code: MRR-A339DAEF9DC3

The Neurovascular Catheters Market was valued at USD 5.40 billion in 2025 and is projected to grow to USD 5.97 billion in 2026, with a CAGR of 12.64%, reaching USD 12.45 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 5.40 billion
Estimated Year [2026] USD 5.97 billion
Forecast Year [2032] USD 12.45 billion
CAGR (%) 12.64%

Framing the critical role of neurovascular catheters in modern endovascular care and the converging clinical, technological, and procurement pressures shaping the field

Neurovascular catheters occupy a pivotal role at the intersection of interventional neurology, endovascular therapy, and acute stroke care. These devices facilitate access, navigation, and delivery of therapeutic agents or implants within cerebral vasculature, enabling procedures ranging from diagnostic angiography to complex aneurysm repair and thrombectomy. Recent advances in microcatheter engineering, refined catheter tip designs, and novel materials have collectively improved deliverability and clinical precision, reducing procedural time and expanding the treatable lesion set. As clinicians push toward less invasive approaches and expanded indications, the importance of catheter performance attributes such as trackability, torque response, and lumen integrity has become paramount.

Clinical pathways and hospital systems are increasingly structured around rapid, protocol-driven interventions for acute neurovascular events, which places greater emphasis on devices that support swift access and reliable performance under emergency conditions. At the same time, the convergence of device innovation, regulatory scrutiny, and payer-driven quality metrics reshapes procurement priorities and vendor relationships. Consequently, manufacturers and health systems must balance technical innovation with manufacturability, sterilization compatibility, and supply resilience. In this dynamic environment, a precise understanding of product differentiation, material trade-offs, and procedural requirements is essential for stakeholders across research and development, clinical leadership, and commercial operations.

This introduction establishes the conceptual frame for subsequent sections by highlighting the technological drivers, clinical imperatives, and system-level pressures that will inform strategic decisions for device designers, hospital supply leaders, and policy stakeholders.

Understanding the pivotal technological, clinical, and regulatory transformations reshaping neurovascular catheter design, adoption dynamics, and supplier value propositions

The neurovascular device landscape is experiencing several transformative shifts driven by technological refinement, procedural standardization, and evolving reimbursement expectations. Engineers are focusing on hybrid constructions that combine flexibility with column strength, enabling long, tortuous navigations without sacrificing support for device delivery. Concurrently, the proliferation of adjunctive devices-such as flow diverters and specialized embolic agents-has altered catheter function requirements, creating demand for differentiated microcatheters optimized for compatibility with emerging therapies.

Clinical pathways are trending toward protocolization of stroke and aneurysm responses, which prioritizes devices that minimize setup and exchange time. This shift incentivizes manufacturers to optimize delivery systems for rapid access, reduce device exchanges, and enhance radiopacity for more efficient fluoroscopic control. Regulatory frameworks are also tightening around post-market surveillance and product traceability, prompting firms to invest in quality systems and data capture mechanisms that demonstrate real-world performance and safety. Financially, health systems are increasingly evaluating total procedural cost and outcome metrics, which encourages vendors to articulate value propositions that go beyond unit price to include device reliability, reduced complication rates, and support for bundled care models.

Taken together, these shifts create a landscape in which innovation is measured not only in technical novelty but also in demonstrable clinical and operational impact. Vendors that can integrate materials science advances with clear clinical utility and supply chain robustness will be best positioned to influence adoption pathways and long-term clinical practice patterns.

Assessing how the introduction of United States tariff adjustments in 2025 will alter sourcing strategies, production footprints, and competitive dynamics across the supply chain

Tariff policy changes in the United States for 2025 present an inflection point for manufacturers, distributors, and hospital purchasing organizations that rely on complex, multi-tiered supply chains. Increased import duties on certain medical components can elevate production costs for devices that incorporate specialized polymers, radiopaque materials, or precision-engineered metal alloys sourced from global suppliers. In response, organizations will reassess sourcing strategies, production footprints, and inventory buffers to mitigate exposure to tariff-driven margin pressure.

Some manufacturers may accelerate strategies to onshore the final assembly of catheters or to qualify domestic suppliers for strategic materials, accepting short-term investment in tooling and validation to secure longer-term pricing stability. Others may pursue tariff classification reviews and supply chain redesigns that emphasize consolidation of shipments and renegotiation of commercial terms with logistics providers to offset cost increases. Health systems and group purchasing organizations will likely pressure vendors for greater transparency on cost drivers and pursue contract mechanisms that share the burden of incremental duties while preserving access to high-performance devices.

Beyond direct cost implications, tariff measures can reshape competitive dynamics by altering the relative cost positions of established multinational suppliers versus regionally based manufacturers. This may spur consolidation among suppliers with complementary capabilities, or create niche opportunities for agile firms that can provide onshore alternatives without compromising on technical performance. Ultimately, tariff effects will be mediated by the capacity of stakeholders to adapt procurement practices, qualify alternative materials, and sustain investments in quality and regulatory compliance amid shifting cost structures.

Deep segmentation-driven insights revealing how product type, materials, sizes, applications, and end-user settings interact to shape design priorities and adoption pathways

A granular view of product, material, size, application, and end-user segmentation illuminates where clinical demand and engineering effort converge. When considering product distinctions, diagnostic catheters are characterized by roles in angiographic imaging and pressure monitoring; guiding catheters are differentiated by reinforced constructions and soft-tip designs that balance support and atraumatic vessel engagement; and microcatheters present choices between over-the-wire systems and rapid exchange formats that influence procedural workflow and companion device compatibility. Material selection plays a central role in device behavior, with polyether block amide offerings prized for flexibility and durability, polyimide used where dimensional stability and heat resistance are required, and polytetrafluoroethylene selected for its lubricity and low friction. Size gradations ranging from 1.2F to 1.5F, 1.6F to 2.0F, and 2.1F to 2.5F correlate directly with the scope of anatomical access and the complexity of devices that can be delivered through a given lumen.

Application-based segmentation further clarifies clinical trajectories: aneurysm treatment strategies encompass endovascular coiling and the growing use of flow diversion devices, embolization procedures may employ liquid or particle embolic agents requiring compatible delivery systems, and thrombectomy tools demand catheters capable of efficient clot engagement and aspiration. The distribution of procedural volume across end users influences product development and commercialization strategies, with ambulatory surgery centers, hospitals, and specialty clinics each presenting distinctive purchasing protocols. Within hospitals, community and tertiary care facilities diverge in case complexity, procedural throughput, and clinical governance, shaping preferred device profiles and supplier relationships. Synthesizing these segmentations highlights the interdependence between device configuration, clinical indication, and point-of-care environment, and underscores the imperative for companies to align product portfolios with nuanced procedural and institutional requirements.

Comparative regional dynamics and strategic imperatives across the Americas, Europe Middle East & Africa, and Asia-Pacific that dictate commercialization and regulatory approaches

Regional dynamics exert a substantial influence on regulatory expectations, clinical practice patterns, and supply chain logistics. In the Americas, patient access models and an emphasis on outcomes-based contracting are driving demand for devices that demonstrate procedural efficiency and reliability, while distribution networks favor vendors that can provide rapid service, training, and post-market support. Reimbursement complexity and hospital consolidation in some markets further shape purchasing timelines and the negotiation leverage of large integrated delivery networks.

Within Europe, the Middle East & Africa, regulatory alignment driven by centralized authorities and regional harmonization efforts impacts product registration strategies and post-market surveillance requirements. Clinical practice variability across countries and variable resource availability create both opportunities and constraints for vendors offering premium designs. In Asia-Pacific, rapid investment in tertiary care centers, growing prevalence of cerebrovascular disease, and increasing procedural volumes are motivating faster adoption of advanced catheter technologies, though fragmented procurement environments and diverse regulatory regimes require tailored market entry approaches. Each region presents distinct paths for clinical engagement, clinician training, and distributor partnerships, and manufacturers must calibrate commercialization strategies that reflect local regulatory timelines, clinician preferences, and logistical realities.

Consequently, a regionally informed approach that integrates regulatory planning, local clinical evidence generation, and adaptive distribution partnerships will be essential for sustained adoption and long-term market relevance.

Analyzing competitive strengths across established global device companies, agile innovators, and strategic manufacturing partners that determine commercial advantage

Competitive landscapes in neurovascular catheters are shaped by a mixture of established device firms and specialized innovators focusing on narrow technical advantages. Leaders in the space typically maintain multi-tiered portfolios that span diagnostic, guiding, and microcatheter offerings and that pair product innovation with investments in clinician training and real-world data collection. These companies emphasize robust quality systems, clear regulatory pathways, and the capacity to support global distribution and service networks.

Smaller, technology-focused firms often differentiate by advancing materials science, proprietary coatings, or novel manufacturing techniques that improve lubricity, kink resistance, or radiopacity. Their agility allows for rapid iteration and close collaboration with key opinion leaders in clinical centers of excellence, creating early adoption opportunities for niche indications. Partnerships between device innovators and makers of therapeutic implants or embolic agents are increasingly common, as integrated solutions enhance procedural efficiency and reduce device exchanges. In parallel, contract manufacturers and component specialists play critical roles by enabling scale-up and cost optimization for advanced polymer and catheter tip assemblies. Overall, competitive advantage stems from a combination of technical credibility, clinical evidence, supply reliability, and the ability to present compelling value in the context of institutional procurement priorities.

Practical, dual-track recommendations for leaders to strengthen supply resilience, accelerate clinically meaningful innovation, and align commercial models with institutional priorities

Industry leaders should adopt a dual-track strategy that balances near-term operational resilience with sustained investment in clinical and technological differentiation. In the immediate term, reassess sourcing and classification of critical materials to blunt exposure to tariff volatility while accelerating supplier qualification programs that diversify geographic risk. Parallel investments in inventory management and demand sensing will reduce the operational disruption from supply chain shocks and support consistent availability in time-sensitive neurovascular procedures.

Strategically, prioritize R&D that addresses clinician-identified pain points such as improved navigability in tortuous anatomies, compatibility with new implantable devices, and designs that reduce exchange steps during procedures. Invest in post-market data capture and real-world evidence generation to substantiate claims of clinical value and to support reimbursement dialogues. Strengthen collaborations with clinical centers for procedural training, simulation-based adoption programs, and iterative feedback loops that inform product refinement. Finally, build commercial models that articulate total procedural value-linking device performance to reduced procedure time, lower complication rates, and improved patient throughput-to align vendor incentives with institutional goals and accelerate uptake across diverse end-user settings.

Transparent and evidence-driven research methodology combining clinician interviews, technical evaluations, regulatory analysis, and supply chain stress-testing to support strategic decisions

The research approach combined a multi-tiered evidence framework that synthesizes primary clinician inputs, engineering assessments, regulatory analysis, and supply chain audits. Primary insights were gathered through structured interviews with interventional neurologists, neurointerventional radiologists, and procurement leaders, supplemented by technical consultations with design engineers and materials scientists. Secondary sources encompassed peer-reviewed clinical literature, device labeling standards, and publicly accessible regulatory filings, which informed device performance context and safety considerations. Supply chain assessments included mapping of material inputs, manufacturing steps, and logistics nodes to identify potential vulnerability points and resilience opportunities.

Analytical methods incorporated comparative device profiling, materials property evaluation, and scenario-based stress testing of supply chain configurations under tariff and logistical disruption scenarios. Where possible, triangulation across data streams ensured robustness of findings: clinical preferences were cross-referenced with design feature sets, and regulatory timelines were evaluated against product development roadmaps. Throughout the process, attention was paid to potential bias and to the validation of technical claims through engineering verification and clinician corroboration, yielding a pragmatic and evidence-grounded perspective that supports operational decision-making and product strategy refinement.

Synthesis of clinical, technical, and operational imperatives that conclude with strategic clarity on where stakeholders must focus to sustain adoption and reduce risk

The neurovascular catheter landscape is defined by rapid technical evolution, shifting clinical protocols, and an increasingly complex supply and regulatory environment. Device makers and health systems alike face the dual imperatives of delivering high-performance solutions for delicate cerebrovascular interventions while maintaining resilient, cost-effective supply chains. Material innovations and refined catheter architectures are expanding procedural capabilities, yet adoption hinges on demonstrable clinical benefits and operational advantages that resonate with institutional purchasers and clinical teams.

Tariff-driven cost pressures and regional regulatory subtleties demand proactive supply chain and commercialization planning, and companies that integrate materials strategy, clinician collaboration, and regional market intelligence will be best positioned to navigate uncertainty. By aligning product development with clinician-identified needs, investing in real-world evidence, and building flexible sourcing models, stakeholders can both accelerate adoption and reduce systemic risk. The combined result is a field that rewards technical excellence paired with pragmatic execution and an orientation toward measurable clinical and operational outcomes.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Neurovascular Catheters Market, by Product Type

  • 8.1. Diagnostic Catheters
    • 8.1.1. Angiographic Diagnostic
    • 8.1.2. Pressure Monitoring
  • 8.2. Guiding Catheters
    • 8.2.1. Reinforced
    • 8.2.2. Soft Tip
  • 8.3. Microcatheters
    • 8.3.1. Over The Wire
    • 8.3.2. Rapid Exchange

9. Neurovascular Catheters Market, by Material

  • 9.1. Polyether Block Amide
  • 9.2. Polyimide
  • 9.3. Polytetrafluoroethylene

10. Neurovascular Catheters Market, by Size

  • 10.1. 1.2F To 1.5F
  • 10.2. 1.6F To 2.0F
  • 10.3. 2.1F To 2.5F

11. Neurovascular Catheters Market, by Application

  • 11.1. Aneurysm Treatment
    • 11.1.1. Endovascular Coiling
    • 11.1.2. Flow Diversion Devices
  • 11.2. Embolization Procedures
    • 11.2.1. Liquid Embolization
    • 11.2.2. Particle Embolization
  • 11.3. Thrombectomy

12. Neurovascular Catheters Market, by End User

  • 12.1. Ambulatory Surgery Centers
  • 12.2. Hospitals
    • 12.2.1. Community
    • 12.2.2. Tertiary Care
  • 12.3. Specialty Clinics

13. Neurovascular Catheters Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Neurovascular Catheters Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Neurovascular Catheters Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Neurovascular Catheters Market

17. China Neurovascular Catheters Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Abbott Laboratories
  • 18.6. Acandis GmbH
  • 18.7. Asahi Intecc Co., Ltd.
  • 18.8. B. Braun Melsungen AG
  • 18.9. Balt Extrusion
  • 18.10. Becton, Dickinson and Company
  • 18.11. Boston Scientific Corporation
  • 18.12. Cook Medical LLC
  • 18.13. ICU Medical, Inc.
  • 18.14. Imperative Care Inc.
  • 18.15. Inari Medical, Inc.
  • 18.16. Integer Holdings Corporation
  • 18.17. Integra LifeSciences Holdings Corporation
  • 18.18. Johnson & Johnson Services, Inc.
  • 18.19. Medtronic plc
  • 18.20. Merit Medical Systems, Inc.
  • 18.21. MicroPort Scientific Corporation
  • 18.22. Penumbra, Inc.
  • 18.23. Phenox GmbH
  • 18.24. Rapid Medical Ltd.
  • 18.25. Stryker Corporation
  • 18.26. Teleflex Incorporated
  • 18.27. Terumo Company
  • 18.28. Terumo Corporation
  • 18.29. Zeus Industrial Products, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL NEUROVASCULAR CATHETERS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL NEUROVASCULAR CATHETERS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL NEUROVASCULAR CATHETERS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL NEUROVASCULAR CATHETERS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL NEUROVASCULAR CATHETERS MARKET SIZE, BY MATERIAL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL NEUROVASCULAR CATHETERS MARKET SIZE, BY SIZE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL NEUROVASCULAR CATHETERS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL NEUROVASCULAR CATHETERS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL NEUROVASCULAR CATHETERS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL NEUROVASCULAR CATHETERS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL NEUROVASCULAR CATHETERS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES NEUROVASCULAR CATHETERS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA NEUROVASCULAR CATHETERS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL NEUROVASCULAR CATHETERS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL NEUROVASCULAR CATHETERS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL NEUROVASCULAR CATHETERS MARKET SIZE, BY DIAGNOSTIC CATHETERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL NEUROVASCULAR CATHETERS MARKET SIZE, BY DIAGNOSTIC CATHETERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL NEUROVASCULAR CATHETERS MARKET SIZE, BY DIAGNOSTIC CATHETERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL NEUROVASCULAR CATHETERS MARKET SIZE, BY DIAGNOSTIC CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL NEUROVASCULAR CATHETERS MARKET SIZE, BY ANGIOGRAPHIC DIAGNOSTIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL NEUROVASCULAR CATHETERS MARKET SIZE, BY ANGIOGRAPHIC DIAGNOSTIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL NEUROVASCULAR CATHETERS MARKET SIZE, BY ANGIOGRAPHIC DIAGNOSTIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL NEUROVASCULAR CATHETERS MARKET SIZE, BY PRESSURE MONITORING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL NEUROVASCULAR CATHETERS MARKET SIZE, BY PRESSURE MONITORING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL NEUROVASCULAR CATHETERS MARKET SIZE, BY PRESSURE MONITORING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL NEUROVASCULAR CATHETERS MARKET SIZE, BY GUIDING CATHETERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL NEUROVASCULAR CATHETERS MARKET SIZE, BY GUIDING CATHETERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL NEUROVASCULAR CATHETERS MARKET SIZE, BY GUIDING CATHETERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL NEUROVASCULAR CATHETERS MARKET SIZE, BY GUIDING CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL NEUROVASCULAR CATHETERS MARKET SIZE, BY REINFORCED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL NEUROVASCULAR CATHETERS MARKET SIZE, BY REINFORCED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL NEUROVASCULAR CATHETERS MARKET SIZE, BY REINFORCED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL NEUROVASCULAR CATHETERS MARKET SIZE, BY SOFT TIP, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL NEUROVASCULAR CATHETERS MARKET SIZE, BY SOFT TIP, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL NEUROVASCULAR CATHETERS MARKET SIZE, BY SOFT TIP, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL NEUROVASCULAR CATHETERS MARKET SIZE, BY MICROCATHETERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL NEUROVASCULAR CATHETERS MARKET SIZE, BY MICROCATHETERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL NEUROVASCULAR CATHETERS MARKET SIZE, BY MICROCATHETERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL NEUROVASCULAR CATHETERS MARKET SIZE, BY MICROCATHETERS, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL NEUROVASCULAR CATHETERS MARKET SIZE, BY OVER THE WIRE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL NEUROVASCULAR CATHETERS MARKET SIZE, BY OVER THE WIRE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL NEUROVASCULAR CATHETERS MARKET SIZE, BY OVER THE WIRE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL NEUROVASCULAR CATHETERS MARKET SIZE, BY RAPID EXCHANGE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL NEUROVASCULAR CATHETERS MARKET SIZE, BY RAPID EXCHANGE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL NEUROVASCULAR CATHETERS MARKET SIZE, BY RAPID EXCHANGE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL NEUROVASCULAR CATHETERS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL NEUROVASCULAR CATHETERS MARKET SIZE, BY POLYETHER BLOCK AMIDE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL NEUROVASCULAR CATHETERS MARKET SIZE, BY POLYETHER BLOCK AMIDE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL NEUROVASCULAR CATHETERS MARKET SIZE, BY POLYETHER BLOCK AMIDE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL NEUROVASCULAR CATHETERS MARKET SIZE, BY POLYIMIDE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL NEUROVASCULAR CATHETERS MARKET SIZE, BY POLYIMIDE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL NEUROVASCULAR CATHETERS MARKET SIZE, BY POLYIMIDE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL NEUROVASCULAR CATHETERS MARKET SIZE, BY POLYTETRAFLUOROETHYLENE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL NEUROVASCULAR CATHETERS MARKET SIZE, BY POLYTETRAFLUOROETHYLENE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL NEUROVASCULAR CATHETERS MARKET SIZE, BY POLYTETRAFLUOROETHYLENE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL NEUROVASCULAR CATHETERS MARKET SIZE, BY SIZE, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL NEUROVASCULAR CATHETERS MARKET SIZE, BY 1.2F TO 1.5F, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL NEUROVASCULAR CATHETERS MARKET SIZE, BY 1.2F TO 1.5F, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL NEUROVASCULAR CATHETERS MARKET SIZE, BY 1.2F TO 1.5F, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL NEUROVASCULAR CATHETERS MARKET SIZE, BY 1.6F TO 2.0F, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL NEUROVASCULAR CATHETERS MARKET SIZE, BY 1.6F TO 2.0F, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL NEUROVASCULAR CATHETERS MARKET SIZE, BY 1.6F TO 2.0F, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL NEUROVASCULAR CATHETERS MARKET SIZE, BY 2.1F TO 2.5F, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL NEUROVASCULAR CATHETERS MARKET SIZE, BY 2.1F TO 2.5F, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL NEUROVASCULAR CATHETERS MARKET SIZE, BY 2.1F TO 2.5F, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL NEUROVASCULAR CATHETERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL NEUROVASCULAR CATHETERS MARKET SIZE, BY ANEURYSM TREATMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL NEUROVASCULAR CATHETERS MARKET SIZE, BY ANEURYSM TREATMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL NEUROVASCULAR CATHETERS MARKET SIZE, BY ANEURYSM TREATMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL NEUROVASCULAR CATHETERS MARKET SIZE, BY ANEURYSM TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL NEUROVASCULAR CATHETERS MARKET SIZE, BY ENDOVASCULAR COILING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL NEUROVASCULAR CATHETERS MARKET SIZE, BY ENDOVASCULAR COILING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL NEUROVASCULAR CATHETERS MARKET SIZE, BY ENDOVASCULAR COILING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL NEUROVASCULAR CATHETERS MARKET SIZE, BY FLOW DIVERSION DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL NEUROVASCULAR CATHETERS MARKET SIZE, BY FLOW DIVERSION DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL NEUROVASCULAR CATHETERS MARKET SIZE, BY FLOW DIVERSION DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL NEUROVASCULAR CATHETERS MARKET SIZE, BY EMBOLIZATION PROCEDURES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL NEUROVASCULAR CATHETERS MARKET SIZE, BY EMBOLIZATION PROCEDURES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL NEUROVASCULAR CATHETERS MARKET SIZE, BY EMBOLIZATION PROCEDURES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL NEUROVASCULAR CATHETERS MARKET SIZE, BY EMBOLIZATION PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL NEUROVASCULAR CATHETERS MARKET SIZE, BY LIQUID EMBOLIZATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL NEUROVASCULAR CATHETERS MARKET SIZE, BY LIQUID EMBOLIZATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL NEUROVASCULAR CATHETERS MARKET SIZE, BY LIQUID EMBOLIZATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL NEUROVASCULAR CATHETERS MARKET SIZE, BY PARTICLE EMBOLIZATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL NEUROVASCULAR CATHETERS MARKET SIZE, BY PARTICLE EMBOLIZATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL NEUROVASCULAR CATHETERS MARKET SIZE, BY PARTICLE EMBOLIZATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL NEUROVASCULAR CATHETERS MARKET SIZE, BY THROMBECTOMY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL NEUROVASCULAR CATHETERS MARKET SIZE, BY THROMBECTOMY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL NEUROVASCULAR CATHETERS MARKET SIZE, BY THROMBECTOMY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL NEUROVASCULAR CATHETERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL NEUROVASCULAR CATHETERS MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL NEUROVASCULAR CATHETERS MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL NEUROVASCULAR CATHETERS MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL NEUROVASCULAR CATHETERS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL NEUROVASCULAR CATHETERS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL NEUROVASCULAR CATHETERS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL NEUROVASCULAR CATHETERS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL NEUROVASCULAR CATHETERS MARKET SIZE, BY COMMUNITY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL NEUROVASCULAR CATHETERS MARKET SIZE, BY COMMUNITY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL NEUROVASCULAR CATHETERS MARKET SIZE, BY COMMUNITY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL NEUROVASCULAR CATHETERS MARKET SIZE, BY TERTIARY CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL NEUROVASCULAR CATHETERS MARKET SIZE, BY TERTIARY CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL NEUROVASCULAR CATHETERS MARKET SIZE, BY TERTIARY CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL NEUROVASCULAR CATHETERS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL NEUROVASCULAR CATHETERS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL NEUROVASCULAR CATHETERS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL NEUROVASCULAR CATHETERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. AMERICAS NEUROVASCULAR CATHETERS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 96. AMERICAS NEUROVASCULAR CATHETERS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 97. AMERICAS NEUROVASCULAR CATHETERS MARKET SIZE, BY DIAGNOSTIC CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 98. AMERICAS NEUROVASCULAR CATHETERS MARKET SIZE, BY GUIDING CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 99. AMERICAS NEUROVASCULAR CATHETERS MARKET SIZE, BY MICROCATHETERS, 2018-2032 (USD MILLION)
  • TABLE 100. AMERICAS NEUROVASCULAR CATHETERS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 101. AMERICAS NEUROVASCULAR CATHETERS MARKET SIZE, BY SIZE, 2018-2032 (USD MILLION)
  • TABLE 102. AMERICAS NEUROVASCULAR CATHETERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 103. AMERICAS NEUROVASCULAR CATHETERS MARKET SIZE, BY ANEURYSM TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 104. AMERICAS NEUROVASCULAR CATHETERS MARKET SIZE, BY EMBOLIZATION PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 105. AMERICAS NEUROVASCULAR CATHETERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 106. AMERICAS NEUROVASCULAR CATHETERS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 107. NORTH AMERICA NEUROVASCULAR CATHETERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. NORTH AMERICA NEUROVASCULAR CATHETERS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. NORTH AMERICA NEUROVASCULAR CATHETERS MARKET SIZE, BY DIAGNOSTIC CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 110. NORTH AMERICA NEUROVASCULAR CATHETERS MARKET SIZE, BY GUIDING CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 111. NORTH AMERICA NEUROVASCULAR CATHETERS MARKET SIZE, BY MICROCATHETERS, 2018-2032 (USD MILLION)
  • TABLE 112. NORTH AMERICA NEUROVASCULAR CATHETERS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 113. NORTH AMERICA NEUROVASCULAR CATHETERS MARKET SIZE, BY SIZE, 2018-2032 (USD MILLION)
  • TABLE 114. NORTH AMERICA NEUROVASCULAR CATHETERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA NEUROVASCULAR CATHETERS MARKET SIZE, BY ANEURYSM TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 116. NORTH AMERICA NEUROVASCULAR CATHETERS MARKET SIZE, BY EMBOLIZATION PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA NEUROVASCULAR CATHETERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA NEUROVASCULAR CATHETERS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 119. LATIN AMERICA NEUROVASCULAR CATHETERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. LATIN AMERICA NEUROVASCULAR CATHETERS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. LATIN AMERICA NEUROVASCULAR CATHETERS MARKET SIZE, BY DIAGNOSTIC CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA NEUROVASCULAR CATHETERS MARKET SIZE, BY GUIDING CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 123. LATIN AMERICA NEUROVASCULAR CATHETERS MARKET SIZE, BY MICROCATHETERS, 2018-2032 (USD MILLION)
  • TABLE 124. LATIN AMERICA NEUROVASCULAR CATHETERS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA NEUROVASCULAR CATHETERS MARKET SIZE, BY SIZE, 2018-2032 (USD MILLION)
  • TABLE 126. LATIN AMERICA NEUROVASCULAR CATHETERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 127. LATIN AMERICA NEUROVASCULAR CATHETERS MARKET SIZE, BY ANEURYSM TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 128. LATIN AMERICA NEUROVASCULAR CATHETERS MARKET SIZE, BY EMBOLIZATION PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 129. LATIN AMERICA NEUROVASCULAR CATHETERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 130. LATIN AMERICA NEUROVASCULAR CATHETERS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA NEUROVASCULAR CATHETERS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA NEUROVASCULAR CATHETERS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA NEUROVASCULAR CATHETERS MARKET SIZE, BY DIAGNOSTIC CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA NEUROVASCULAR CATHETERS MARKET SIZE, BY GUIDING CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA NEUROVASCULAR CATHETERS MARKET SIZE, BY MICROCATHETERS, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE, MIDDLE EAST & AFRICA NEUROVASCULAR CATHETERS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE, MIDDLE EAST & AFRICA NEUROVASCULAR CATHETERS MARKET SIZE, BY SIZE, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE, MIDDLE EAST & AFRICA NEUROVASCULAR CATHETERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE, MIDDLE EAST & AFRICA NEUROVASCULAR CATHETERS MARKET SIZE, BY ANEURYSM TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE, MIDDLE EAST & AFRICA NEUROVASCULAR CATHETERS MARKET SIZE, BY EMBOLIZATION PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE, MIDDLE EAST & AFRICA NEUROVASCULAR CATHETERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE, MIDDLE EAST & AFRICA NEUROVASCULAR CATHETERS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE NEUROVASCULAR CATHETERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE NEUROVASCULAR CATHETERS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE NEUROVASCULAR CATHETERS MARKET SIZE, BY DIAGNOSTIC CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE NEUROVASCULAR CATHETERS MARKET SIZE, BY GUIDING CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE NEUROVASCULAR CATHETERS MARKET SIZE, BY MICROCATHETERS, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE NEUROVASCULAR CATHETERS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE NEUROVASCULAR CATHETERS MARKET SIZE, BY SIZE, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE NEUROVASCULAR CATHETERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE NEUROVASCULAR CATHETERS MARKET SIZE, BY ANEURYSM TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE NEUROVASCULAR CATHETERS MARKET SIZE, BY EMBOLIZATION PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE NEUROVASCULAR CATHETERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE NEUROVASCULAR CATHETERS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 155. MIDDLE EAST NEUROVASCULAR CATHETERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. MIDDLE EAST NEUROVASCULAR CATHETERS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. MIDDLE EAST NEUROVASCULAR CATHETERS MARKET SIZE, BY DIAGNOSTIC CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 158. MIDDLE EAST NEUROVASCULAR CATHETERS MARKET SIZE, BY GUIDING CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 159. MIDDLE EAST NEUROVASCULAR CATHETERS MARKET SIZE, BY MICROCATHETERS, 2018-2032 (USD MILLION)
  • TABLE 160. MIDDLE EAST NEUROVASCULAR CATHETERS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 161. MIDDLE EAST NEUROVASCULAR CATHETERS MARKET SIZE, BY SIZE, 2018-2032 (USD MILLION)
  • TABLE 162. MIDDLE EAST NEUROVASCULAR CATHETERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 163. MIDDLE EAST NEUROVASCULAR CATHETERS MARKET SIZE, BY ANEURYSM TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 164. MIDDLE EAST NEUROVASCULAR CATHETERS MARKET SIZE, BY EMBOLIZATION PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 165. MIDDLE EAST NEUROVASCULAR CATHETERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 166. MIDDLE EAST NEUROVASCULAR CATHETERS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 167. AFRICA NEUROVASCULAR CATHETERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 168. AFRICA NEUROVASCULAR CATHETERS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 169. AFRICA NEUROVASCULAR CATHETERS MARKET SIZE, BY DIAGNOSTIC CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 170. AFRICA NEUROVASCULAR CATHETERS MARKET SIZE, BY GUIDING CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 171. AFRICA NEUROVASCULAR CATHETERS MARKET SIZE, BY MICROCATHETERS, 2018-2032 (USD MILLION)
  • TABLE 172. AFRICA NEUROVASCULAR CATHETERS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 173. AFRICA NEUROVASCULAR CATHETERS MARKET SIZE, BY SIZE, 2018-2032 (USD MILLION)
  • TABLE 174. AFRICA NEUROVASCULAR CATHETERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 175. AFRICA NEUROVASCULAR CATHETERS MARKET SIZE, BY ANEURYSM TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 176. AFRICA NEUROVASCULAR CATHETERS MARKET SIZE, BY EMBOLIZATION PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 177. AFRICA NEUROVASCULAR CATHETERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 178. AFRICA NEUROVASCULAR CATHETERS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 179. ASIA-PACIFIC NEUROVASCULAR CATHETERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 180. ASIA-PACIFIC NEUROVASCULAR CATHETERS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 181. ASIA-PACIFIC NEUROVASCULAR CATHETERS MARKET SIZE, BY DIAGNOSTIC CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 182. ASIA-PACIFIC NEUROVASCULAR CATHETERS MARKET SIZE, BY GUIDING CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 183. ASIA-PACIFIC NEUROVASCULAR CATHETERS MARKET SIZE, BY MICROCATHETERS, 2018-2032 (USD MILLION)
  • TABLE 184. ASIA-PACIFIC NEUROVASCULAR CATHETERS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 185. ASIA-PACIFIC NEUROVASCULAR CATHETERS MARKET SIZE, BY SIZE, 2018-2032 (USD MILLION)
  • TABLE 186. ASIA-PACIFIC NEUROVASCULAR CATHETERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 187. ASIA-PACIFIC NEUROVASCULAR CATHETERS MARKET SIZE, BY ANEURYSM TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 188. ASIA-PACIFIC NEUROVASCULAR CATHETERS MARKET SIZE, BY EMBOLIZATION PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 189. ASIA-PACIFIC NEUROVASCULAR CATHETERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 190. ASIA-PACIFIC NEUROVASCULAR CATHETERS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 191. GLOBAL NEUROVASCULAR CATHETERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 192. ASEAN NEUROVASCULAR CATHETERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 193. ASEAN NEUROVASCULAR CATHETERS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. ASEAN NEUROVASCULAR CATHETERS MARKET SIZE, BY DIAGNOSTIC CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 195. ASEAN NEUROVASCULAR CATHETERS MARKET SIZE, BY GUIDING CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 196. ASEAN NEUROVASCULAR CATHETERS MARKET SIZE, BY MICROCATHETERS, 2018-2032 (USD MILLION)
  • TABLE 197. ASEAN NEUROVASCULAR CATHETERS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 198. ASEAN NEUROVASCULAR CATHETERS MARKET SIZE, BY SIZE, 2018-2032 (USD MILLION)
  • TABLE 199. ASEAN NEUROVASCULAR CATHETERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 200. ASEAN NEUROVASCULAR CATHETERS MARKET SIZE, BY ANEURYSM TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 201. ASEAN NEUROVASCULAR CATHETERS MARKET SIZE, BY EMBOLIZATION PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 202. ASEAN NEUROVASCULAR CATHETERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 203. ASEAN NEUROVASCULAR CATHETERS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 204. GCC NEUROVASCULAR CATHETERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 205. GCC NEUROVASCULAR CATHETERS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 206. GCC NEUROVASCULAR CATHETERS MARKET SIZE, BY DIAGNOSTIC CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 207. GCC NEUROVASCULAR CATHETERS MARKET SIZE, BY GUIDING CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 208. GCC NEUROVASCULAR CATHETERS MARKET SIZE, BY MICROCATHETERS, 2018-2032 (USD MILLION)
  • TABLE 209. GCC NEUROVASCULAR CATHETERS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 210. GCC NEUROVASCULAR CATHETERS MARKET SIZE, BY SIZE, 2018-2032 (USD MILLION)
  • TABLE 211. GCC NEUROVASCULAR CATHETERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 212. GCC NEUROVASCULAR CATHETERS MARKET SIZE, BY ANEURYSM TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 213. GCC NEUROVASCULAR CATHETERS MARKET SIZE, BY EMBOLIZATION PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 214. GCC NEUROVASCULAR CATHETERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 215. GCC NEUROVASCULAR CATHETERS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 216. EUROPEAN UNION NEUROVASCULAR CATHETERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 217. EUROPEAN UNION NEUROVASCULAR CATHETERS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 218. EUROPEAN UNION NEUROVASCULAR CATHETERS MARKET SIZE, BY DIAGNOSTIC CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 219. EUROPEAN UNION NEUROVASCULAR CATHETERS MARKET SIZE, BY GUIDING CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPEAN UNION NEUROVASCULAR CATHETERS MARKET SIZE, BY MICROCATHETERS, 2018-2032 (USD MILLION)
  • TABLE 221. EUROPEAN UNION NEUROVASCULAR CATHETERS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 222. EUROPEAN UNION NEUROVASCULAR CATHETERS MARKET SIZE, BY SIZE, 2018-2032 (USD MILLION)
  • TABLE 223. EUROPEAN UNION NEUROVASCULAR CATHETERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 224. EUROPEAN UNION NEUROVASCULAR CATHETERS MARKET SIZE, BY ANEURYSM TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 225. EUROPEAN UNION NEUROVASCULAR CATHETERS MARKET SIZE, BY EMBOLIZATION PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 226. EUROPEAN UNION NEUROVASCULAR CATHETERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 227. EUROPEAN UNION NEUROVASCULAR CATHETERS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 228. BRICS NEUROVASCULAR CATHETERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 229. BRICS NEUROVASCULAR CATHETERS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 230. BRICS NEUROVASCULAR CATHETERS MARKET SIZE, BY DIAGNOSTIC CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 231. BRICS NEUROVASCULAR CATHETERS MARKET SIZE, BY GUIDING CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 232. BRICS NEUROVASCULAR CATHETERS MARKET SIZE, BY MICROCATHETERS, 2018-2032 (USD MILLION)
  • TABLE 233. BRICS NEUROVASCULAR CATHETERS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 234. BRICS NEUROVASCULAR CATHETERS MARKET SIZE, BY SIZE, 2018-2032 (USD MILLION)
  • TABLE 235. BRICS NEUROVASCULAR CATHETERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 236. BRICS NEUROVASCULAR CATHETERS MARKET SIZE, BY ANEURYSM TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 237. BRICS NEUROVASCULAR CATHETERS MARKET SIZE, BY EMBOLIZATION PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 238. BRICS NEUROVASCULAR CATHETERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 239. BRICS NEUROVASCULAR CATHETERS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 240. G7 NEUROVASCULAR CATHETERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 241. G7 NEUROVASCULAR CATHETERS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 242. G7 NEUROVASCULAR CATHETERS MARKET SIZE, BY DIAGNOSTIC CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 243. G7 NEUROVASCULAR CATHETERS MARKET SIZE, BY GUIDING CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 244. G7 NEUROVASCULAR CATHETERS MARKET SIZE, BY MICROCATHETERS, 2018-2032 (USD MILLION)
  • TABLE 245. G7 NEUROVASCULAR CATHETERS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 246. G7 NEUROVASCULAR CATHETERS MARKET SIZE, BY SIZE, 2018-2032 (USD MILLION)
  • TABLE 247. G7 NEUROVASCULAR CATHETERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 248. G7 NEUROVASCULAR CATHETERS MARKET SIZE, BY ANEURYSM TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 249. G7 NEUROVASCULAR CATHETERS MARKET SIZE, BY EMBOLIZATION PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 250. G7 NEUROVASCULAR CATHETERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 251. G7 NEUROVASCULAR CATHETERS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 252. NATO NEUROVASCULAR CATHETERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 253. NATO NEUROVASCULAR CATHETERS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 254. NATO NEUROVASCULAR CATHETERS MARKET SIZE, BY DIAGNOSTIC CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 255. NATO NEUROVASCULAR CATHETERS MARKET SIZE, BY GUIDING CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 256. NATO NEUROVASCULAR CATHETERS MARKET SIZE, BY MICROCATHETERS, 2018-2032 (USD MILLION)
  • TABLE 257. NATO NEUROVASCULAR CATHETERS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 258. NATO NEUROVASCULAR CATHETERS MARKET SIZE, BY SIZE, 2018-2032 (USD MILLION)
  • TABLE 259. NATO NEUROVASCULAR CATHETERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 260. NATO NEUROVASCULAR CATHETERS MARKET SIZE, BY ANEURYSM TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 261. NATO NEUROVASCULAR CATHETERS MARKET SIZE, BY EMBOLIZATION PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 262. NATO NEUROVASCULAR CATHETERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 263. NATO NEUROVASCULAR CATHETERS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 264. GLOBAL NEUROVASCULAR CATHETERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 265. UNITED STATES NEUROVASCULAR CATHETERS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 266. UNITED STATES NEUROVASCULAR CATHETERS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 267. UNITED STATES NEUROVASCULAR CATHETERS MARKET SIZE, BY DIAGNOSTIC CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 268. UNITED STATES NEUROVASCULAR CATHETERS MARKET SIZE, BY GUIDING CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 269. UNITED STATES NEUROVASCULAR CATHETERS MARKET SIZE, BY MICROCATHETERS, 2018-2032 (USD MILLION)
  • TABLE 270. UNITED STATES NEUROVASCULAR CATHETERS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 271. UNITED STATES NEUROVASCULAR CATHETERS MARKET SIZE, BY SIZE, 2018-2032 (USD MILLION)
  • TABLE 272. UNITED STATES NEUROVASCULAR CATHETERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 273. UNITED STATES NEUROVASCULAR CATHETERS MARKET SIZE, BY ANEURYSM TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 274. UNITED STATES NEUROVASCULAR CATHETERS MARKET SIZE, BY EMBOLIZATION PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 275. UNITED STATES NEUROVASCULAR CATHETERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 276. UNITED STATES NEUROVASCULAR CATHETERS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 277. CHINA NEUROVASCULAR CATHETERS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 278. CHINA NEUROVASCULAR CATHETERS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 279. CHINA NEUROVASCULAR CATHETERS MARKET SIZE, BY DIAGNOSTIC CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 280. CHINA NEUROVASCULAR CATHETERS MARKET SIZE, BY GUIDING CATHETERS, 2018-2032 (USD MILLION)
  • TABLE 281. CHINA NEUROVASCULAR CATHETERS MARKET SIZE, BY MICROCATHETERS, 2018-2032 (USD MILLION)
  • TABLE 282. CHINA NEUROVASCULAR CATHETERS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 283. CHINA NEUROVASCULAR CATHETERS MARKET SIZE, BY SIZE, 2018-2032 (USD MILLION)
  • TABLE 284. CHINA NEUROVASCULAR CATHETERS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 285. CHINA NEUROVASCULAR CATHETERS MARKET SIZE, BY ANEURYSM TREATMENT, 2018-2032 (USD MILLION)
  • TABLE 286. CHINA NEUROVASCULAR CATHETERS MARKET SIZE, BY EMBOLIZATION PROCEDURES, 2018-2032 (USD MILLION)
  • TABLE 287. CHINA NEUROVASCULAR CATHETERS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 288. CHINA NEUROVASCULAR CATHETERS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)